Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Purple Biotech ( (PPBT) ) just unveiled an announcement.
On September 4, 2025, Purple Biotech announced the pricing of a public offering expected to raise approximately $6 million upfront, with potential additional proceeds of up to $12 million from short-term warrants. The funds will be used for developing oncology therapeutic candidates and general corporate purposes. This move is expected to bolster Purple Biotech’s financial position and support its ongoing research and development efforts in the oncology sector.
The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focusing on developing first-in-class therapies to combat tumor immune evasion and drug resistance. Their oncology pipeline includes CAPTN-3, CM24, and NT219, which are designed to enhance immune responses within the tumor microenvironment. The company is based in Rehovot, Israel.
Average Trading Volume: 874,307
Technical Sentiment Signal: Sell
Current Market Cap: $2.7M
Learn more about PPBT stock on TipRanks’ Stock Analysis page.